Allergan, Inc. had no role in study design, data collection, data analysis, data interpretation, or writing of the report.
Letter to the Editor
Version of Record online: 22 MAR 2011
Copyright © 2011 Movement Disorder Society
Volume 26, Issue 5, pages 913–914, April 2011
How to Cite
Espay, A. J., Vaughan, J. E., Shukla, R., Gartner, M., Sahay, A., Revilla, F. J. and Duker, A. P. (2011), Botulinum toxin type A for Levodopa-induced cervical dyskinesias in Parkinson's disease: Unfavorable risk-benefit ratio. Mov. Disord., 26: 913–914. doi: 10.1002/mds.23522
Relevant conflict of interest/financial disclosures: Nothing to report.
Full financial disclosures and author roles may be found in the online version of this article.
- Issue online: 21 APR 2011
- Version of Record online: 22 MAR 2011
Additional Supporting Information may be found in the online version of this article.
|MDS_23522_sm_SuppInfoF1.doc||36K||Supporting Figure 1|
|MDS_23522_sm_Authorroles.doc||24K||Author Roles and Disclosures|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.